Effects of Chromium Picolinate on Food Intake
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to test the effects of chromium picolinate on food intake, food cravings, eating attitudes, and appetite. If chromium picolinate is found to have a beneficial impact on satiety and food intake, then this supplement may be an alternative or adjunctive treatment for overweight people desiring to modify their food intake. The primary hypothesis of this study is that among individuals who report being carbohydrate cravers, chromium picolinate supplementation will reduce food intake during a test lunch meal and produce greater satiety in comparison to a placebo.
| Condition | Intervention |
|---|---|
|
Obesity Atypical Depression |
Drug: Chromium Picolinate |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Prevention |
Eligibility| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Inclusion criteria are:
- Healthy female who has not been diagnosed with diabetes, cardiovascular illness, or other chronic diseases,
- Food craver, determined by self-reported craving for carbohydrates on two out of three validated measures of food cravings,
- > 18 years of age and < 50 years of age, and
- Body mass index between 25 and 39.9 kg/m2. Participants will be scheduled for testing during the luteal phase of their menstrual cycle to limit the confounding effect of the menstrual cycle on energy intake. We will include women who are taking monophasic oral contraceptives but will exclude other oral contraceptive regimens. Participants with very irregular menstrual cycles will also be excluded because this irregularity will make it very difficult to schedule testing during the luteal phase of the menstrual cycle.
Exclusion Criteria:
Potential participants will be excluded for the following reasons:
- Participants who report smoking cigarettes will be excluded because of the effects of nicotine upon taste and appetite,
- Participants who have a diagnosable eating disorder (i.e., anorexia or bulimia nervosa) will also be excluded since intentional restriction of eating and binge eating/overeating could increase the variability of the data,
- Participants who report using diet pills will be excluded since diet pills may potentially influence appetite, hunger, and/or satiety,
- Participants will be excluded if they are taking anti-depressant medications, anti-psychotic medications, or any medications that may potentially influence appetite, hunger, and/or satiety,
- Participants who are not determined to be carbohydrate cravers will be excluded,
- Participants will also be excluded if they report any allergies to the foods that will be used in the study.
Contacts and Locations| United States, Louisiana | |
| Pennington Biomedical Research Center | |
| Baton Rouge, Louisiana, United States, 70808 | |
| Principal Investigator: | Stephen D Anton, Ph.D. | Pennington Biomedical Research Center |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00477854 History of Changes |
| Other Study ID Numbers: | 24040 |
| Study First Received: | May 23, 2007 |
| Last Updated: | May 23, 2007 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Depression Depressive Disorder Obesity Behavioral Symptoms Mood Disorders Mental Disorders Overnutrition Nutrition Disorders Overweight Body Weight Signs and Symptoms |
Chromium Picolinic acid Trace Elements Micronutrients Growth Substances Physiological Effects of Drugs Pharmacologic Actions Iron Chelating Agents Chelating Agents Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 19, 2013